Theravance, Inc. (NASDAQ: THRX) announced today that the European Medicines Agency (EMEA) has completed the validation phase for the Marketing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE